Assessment of Actin FS and Actin FSL sensitivity to specific clotting factor deficiencies.
We present a two centre study designed to assess the sensitivity of Actin FS and Actin FSL to deficiencies of factor VIII, IX, XI or XII. The study was undertaken at two centres to avoid bias due to the investigations being undertaken on one analyser. Samples from patients with a factor VIII (n = 36, F VIII = < 1.0-50 iu/dl), factor IX (n = 22, F IX = 2-48 iu/dl), factor XI (n = 23, F XI = 5-50 u/dl) or a factor XII (n = 18, F XII = 1-50 u/dl) deficient state were studied. Activated partial thromboplastin times (APTT) were determined using two batches of Actin FS and of Actin FSL; comparison of APTT results between centres was facilitated by the conversion of clotting times to ratios (test divided by geometric mean normal clotting time). APTT ratios were considered to be elevated if greater than two standard deviations above the mean normal. The factor deficient status of each sample was verified by assaying all samples for factors VIII, IX, XI and XII. Clotting factor assays were performed on a Sysmex CA-1000 fitted with research software, which permitted the auto-dilution and testing of three serial dilution of both a reference preparation and each patient's sample. Assay results were calculated using parallel-line Bioassay principles. This procedure allowed for variation in clotting times due to the effect of temporal drift of any of the reagents within the assay system. Actin FS and Actin FSL demonstrate acceptable sensitivity to factor VIII deficiency, however, both reagents failed to detect a large proportion of factor XI (17.4% and 30.4% of samples, respectively) and factor XII (66.7% and 72.2%, respectively) deficiencies. The detection rate with Actin FSL for factor IX deficiency was also poor (36.4% not detected). As factor IX and XI deficiencies are both associated with haemorrhagic disorders, the inability of these reagents to detect such abnormalities gave cause for concern.
Lawrie
A S
AS
Department of Haematology, University College London, UK.
Kitchen
S
S
Purdy
G
G
Mackie
I J
IJ
Preston
F E
FE
Machin
S J
SJ
D000199:Actins / Q000378:metabolism*; D001778:Blood Coagulation Disorders / Q000097:blood / Q000175:diagnosis*; D004355:Drug Stability; D004356:Drug Storage; D004610:Ellagic Acid / Q000378:metabolism*; D005069:Evaluation Studies as Topic; D005164:Factor IX / Q000032:analysis; D005169:Factor VIII / Q000032:analysis; D005172:Factor XI / Q000032:analysis; D005173:Factor XI Deficiency / Q000097:blood / Q000175:diagnosis; D005174:Factor XII / Q000032:analysis; D005175:Factor XII Deficiency / Q000097:blood / Q000175:diagnosis; D005340:Fibrinogen / Q000032:analysis; D006467:Hemophilia A / Q000097:blood / Q000175:diagnosis; D002836:Hemophilia B / Q000097:blood / Q000175:diagnosis; D006493:Heparin / Q000097:blood / Q000494:pharmacology; D006801:Humans; D007202:Indicators and Reagents; D016682:Lupus Coagulation Inhibitor / Q000378:metabolism*; D008403:Mass Screening; D015588:Observer Variation; D010314:Partial Thromboplastin Time; D011237:Predictive Value of Tests; D011517:Prothrombin Time; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D013918:Thrombin Time
D000199:Actins; D007202:Indicators and Reagents; D016682:Lupus Coagulation Inhibitor; D004610:Ellagic Acid; D005169:Factor VIII; D005164:Factor IX; D005174:Factor XII; D005340:Fibrinogen; D006493:Heparin; D005172:Factor XI